This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC ...

A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website. About Dianthus Therapeutics Dianthus Therapeutics, Inc. is a ...

Choosing the right plants is key to creating the hummingbird garden of your dreams. This dynamic plant duo provides tons of ...

Dianthus Therapeutics is on a mission to reduce the number of injections autoimmune disease patients have to receive, using $100 million in series A financing to send its antibody candidate into the ...

Dianthus Therapeutics (NASDAQ:DNTH) announced a licensing deal worth up to $1B with Nanjing Leads Biolabs on Thursday to obtain exclusive rights to an autoimmune disease therapy developed by the ...

Dianthus Therapeutics (DNTH) revealed a new licensing agreement with Nanjing Leads Biolabs for the global rights to DNTH212, a promising autoimmune disease treatment, outside Greater China. The FDA ...

We recently published 10 Stocks With Eye-Popping Gains; 7 Soar to Fresh Highs. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is one of the top performers on Monday. Dianthus Therapeutics soared to a new ...

Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase ...

Dianthus Therapeutics (NASDAQ:DNTH) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of ...

Something special is growing in my garden, an unexpected treasure. I love seed packets for their retro beauty, so I'm often extracting the seeds (without damaging the package) and planting them in my ...